Mizuho Securities Reiterates Buy Rating on CVS Health (CVS) Following 3Q EPS Beat

Mizuho Securities analyst Ann Hynes reiterated a Buy rating and $71.00 price target on CVS Health (NYSE: CVS) following the company's 3Q earnings report. CVS reported 3Q:19 EPS of $1.84, above consensus of $1.76. Adjusted operating profit was $3.947bn versus consensus at $3.89bn.

The tone of the conference call was positive. CVS reiterated its 2020 adjusted EPS growth of low-single digits or EPS of at least $7.00. This estimate excludes any benefit from prior period development in the health care benefits segment.

For an analyst ratings summary and ratings history on CVS Health click here. For more ratings news on CVS Health click here.

Shares of CVS Health closed at $71.05 yesterday.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• WM (WM) Tops Q1 EPS by 25c
• CVS Health invests $19.2 million in affordable housing in Arvada, Colorado